Medical Stocks To Watch Today – December 8th

WAVE Life Sciences, Eli Lilly and Company, and Structure Therapeutics are the three Medical stocks to watch today, according to MarketBeat’s stock screener tool. Medical stocks are shares of publicly traded companies whose primary businesses serve the healthcare and medicine markets—such as pharmaceutical and biotechnology firms, medical device manufacturers, diagnostic companies, hospitals, and clinical-service providers. Investors buy medical stocks to gain exposure to drug development, medical technology and healthcare services, but they carry sector-specific risks like regulatory approvals, clinical-trial outcomes, patent expirations and changes in reimbursement. These companies had the highest dollar trading volume of any Medical stocks within the last several days.

WAVE Life Sciences (WVE)

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.

Eli Lilly and Company (LLY)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Structure Therapeutics (GPCR)

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.